Clinical trial · Observational
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT05910710CI-TRIAL-00067324unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It analyzes the Tumor microenvironment(TME) changes in non pathologic complete response(pCR) subjects among subjects who were administered neoadjuvant pembrolizumab and those who were not administered neoadjuvant pembrolizumab for triple negative breast cancer. (Neoadjuvant Weekly paclitaxel, Carboplatin +- Pembrolizumab followed by Doxorubicin, Cyclophosphamide +- Pembrolizumab regimen)
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoadjuvant Chemotherapy | — | UNRESOLVED | — |
| Pembrolizumab | — | UNRESOLVED | — |
| Triple Negative Breast Cancer | Triple-Negative Breast Carcinoma | ALIAS | 0.90 |
| Tumor Microenvironment | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS) | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Subjects administered Neoadjuvant Pembrolizumab
- description
- Neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide add Pembrolizumab
- interventionNames
- Genetic: Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
- label
- Subjects not administered Neoadjuvant Pembrolizumab
- description
- Neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide
- interventionNames
- Genetic: Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
Primary outcomes (1)
- measure
- Genomic profiling will be assessed by tissue and blood samples(analyze the TME changes)
- timeFrame
- 3year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Triple negative breast cancer * Subjects administered neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide add Pembrolizumab or not * Non pCR patients who are undergoing surgery after neoadjuvant chemotherapy * Sign to informed consent Exclusion Criteria: * Patients with difficulty in obtaining sufficient samples
References
Publications (0)
Data not yet available
No reference posted for this study.